Comparative efficacy and safety of 100 mg and 200 mg filgotinib administered to patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Song, Gwan Gyu | - |
dc.contributor.author | Lee, Young Ho | - |
dc.date.accessioned | 2021-08-30T22:21:40Z | - |
dc.date.available | 2021-08-30T22:21:40Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-06 | - |
dc.identifier.issn | 0946-1965 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/55515 | - |
dc.description.abstract | Objectives: We assessed the relative efficacy and safety of once-daily administration of 100 and 200 mg filgotinib (a JAK1-selective inhibitor) in patients with active rheumatoid arthritis (RA). Materials and methods: We conducted a Bayesian network meta-analysis combining the direct and indirect evidence from randomized controlled trials (RCTs) that examined the efficacy and safety of filgotinib in patients with active RA. Results: Five RCTs involving 3,920 patients met the inclusion criteria. There were 15 pairwise comparisons, including 8 direct comparisons and 7 interventions. The ACR20 response rate was significantly higher in the filgotinib 200 mg + methotrexate (MTX) group than in the placebo or placebo + MTX group (odds ratio (OR): 12.39, 95% credible interval (CrI): 3.36 - 45.98.10; OR: 2.68, 95% CrI: 1.80 - 4.39). Compared to the placebo group, the filgotinib 100 mg, adalimumab 40 mg + MTX, filgotinib 200 mg, and placebo + MTX groups showed a significantly higher ACR20 response rate. The ranking probability based on the surface under the cumulative ranking curve (SUCRA) indicated filgotinib 200 mg + MTX was likely to achieve the best ACR20 response rate (SUCRA = 0.902), followed by filgotinib 100 mg + MTX (SUCRA = 0.694), filgotinib 100 mg (SUCRA = 0.675), adalimumab 40 mg + MTX (SUCRA = 0.661), filgotinib 200 mg (SUCRA = 0.305), placebo + MTX (SUCRA = 0.259), and placebo (SUCRA = 0.005). The safety based on the number of serious adverse events (SAEs) did not differ significantly among 6 six interventions. Conclusion: Filgotinib 100 and 200 mg administration once daily in combination with MTX was the most efficacious intervention for active RA, with no significant risk of SAEs. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | DUSTRI-VERLAG DR KARL FEISTLE | - |
dc.subject | DISEASE-ACTIVITY | - |
dc.subject | METHOTREXATE | - |
dc.title | Comparative efficacy and safety of 100 mg and 200 mg filgotinib administered to patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Young Ho | - |
dc.identifier.doi | 10.5414/CP203635 | - |
dc.identifier.scopusid | 2-s2.0-85085264783 | - |
dc.identifier.wosid | 000533629000001 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, v.58, no.6, pp.293 - 298 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS | - |
dc.citation.title | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS | - |
dc.citation.volume | 58 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 293 | - |
dc.citation.endPage | 298 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | DISEASE-ACTIVITY | - |
dc.subject.keywordPlus | METHOTREXATE | - |
dc.subject.keywordAuthor | filgotinib | - |
dc.subject.keywordAuthor | efficacy | - |
dc.subject.keywordAuthor | safety | - |
dc.subject.keywordAuthor | rheumatoid arthritis | - |
dc.subject.keywordAuthor | network meta-analysis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.